Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Flexion Therapeutics, Inc.
Type
Public
Traded as NASDAQ: FLXN
Industry Pharmaceuticals
Headquarters Burlington, MA
Website Flexion Therapeutics

Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.

It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.

In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta". In March 2017 FiercePharma reported that Flexion was in discussions with Sanofi about a possible acquisition, valued at the time at around $1 billion.

Flexion had been developing FX007, a selective small-molecule TrkA inhibitor that it had licensed from AstraZeneca, for osteoarthritis. As of March 2017 Flexion had terminated development. Flexion had also terminated development of FX005, a P38 mitogen-activated protein kinase inhibitor, by that time.

Investment goal date:
Dividends reinvested
Flexion Therapeutics, Inc. FLXN report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-07
--
--
Q4 2017
2018-03-14
--
--
Q4 2017
2018-03-12
--
--
Q3 2017
2017-11-08
--
--
Q3 2017
2017-11-06
-1.0700
0.0000
Q2 2017
2017-08-08
-0.9100
-0.9100
Q1 2017
2017-05-04
-0.7500
-0.7500
Q4 2016
2017-03-09
-0.8000
-0.7900
Q3 2016
2016-11-07
-0.6500
-0.6500
Q2 2016
2016-08-03
-0.6300
-0.6300
Q1 2016
2016-05-12
-0.7800
-0.7800
Q4 2015
2016-03-10
-0.6300
-0.6300
Q3 2015
2015-11-09
-0.5200
-0.5200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
2124208
BlackRock Fund Advisors
1232630
BlackRock Inc.
2112659
BlackRock Institutional Trust Company, N.A.
683076
Capital World Investors
2489000
DRIEHAUS CAPITAL MANAGEMENT LLC
523060
GILDER GAGNON HOWE & CO LLC
4284412
KINGDON CAPITAL MANAGEMENT, L.L.C.
1146551
Novo A/S
1397718
PEREGRINE CAPITAL MANAGEMENT INC /MN/
712631
STATE STREET CORP
829254
TPG Group Holdings (SBS) Advisors, Inc.
936507
Vanguard Group, Inc
995321
WASATCH ADVISORS INC
641474
WELLINGTON MANAGEMENT CO LLP
678226
Major Shareholders
Name Relationship
Total Shares
Holding stocks
PFIZER INC
10.8000% (1687250)
AQXP / CLDN / FLXN /
DRISCOLL FREDERICK W
0.0500% (7777)
FLXN / NVAX / OXGN /
COLELLA SAMUEL D
0.0300% (5000)
MERRIFIELD C ANN
0.0100% (2000)
CBRX / FLXN /
LUBASH BARBARA N
0.1300% (20739)
FLXN /
Bolzon Bradley J PhD
20.5200% (3206807)
FLXN /
5AM Ventures II LP
9.6800% (1512076)
FLXN /
Novo A/S
13.6500% (2133131)
Versant Venture Capital III, L.P.
0.0100% (2250)
FLXN / IMDZ /
Versant Ventures III, LLC
0.1300% (20739)
FLXN / VCYT /
Stejbach Mark
0.0100% (1580)
ALKS / FLXN / TNGN /
Sofinnova Partners SAS
13.4100% (2095491)
FLXN /
Clayman Michael D.
0.1900% (30395)
AKBA / FLXN /
Clayman Michael D.
0.2300% (35395)
AKBA / FLXN /
Tordjman Rafael
13.4800% (2105491)
FLXN /
Bodick Neil
0.4000% (62905)
FLXN /
Schwab Andrew J.
9.6800% (1512076)
FLXN /
% ()